CLINICOPATHOLOGICAL AND PROGNOSTIC SIGNIFICANCE OF PLATELET TO LYMPHOCYTE RATIO IN DIFFUSE LARGE B-CELL LYMPHOMA: A META-ANALYSIS | ||||
| Bulletin of Pharmaceutical Sciences Assiut University | ||||
| Volume 46, Issue 1, June 2023, Page 291-304 PDF (1.31 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/bfsa.2023.300949 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Haitham Saeed1; Mohamed EA Shaaban2; Mohamed E.A. Abdelrahim   1
| ||||
| 1Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt | ||||
| 2Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt | ||||
| Abstract | ||||
| Background: Nowadays, there is a significant but variable correlation between the diffuse large B-cell lymphoma (DLBL) and the platelet-lymphocyte ratio (PLR). This meta-analysis will assess this association. Methods: A thorough search was done up until June 2022, and 11 research revealed 2284 patients with DLBL. They discovered a connection between DLBL and the PLR. A fixed or random-effect model was used to construct odds ratios (ORs) with 95% confidence intervals (CIs) and examine the prognostic significance of the PLR on overall survival, progression-free survival, and a variety of clinicopathological characteristics. Results: Poor 5-years overall survival (OR, 0.59; 95% CI, 0.36-0.98, p<0.001), poor 2-years progression-free survival subjects (OR, 0.42; 95% CI, 0.27-0.67, p<0.001), and poor 5-years progression-free survival (OR, 0.50; 95% CI, 0.34-0.72, p<0.001) were all significantly correlated with high the PLR. In a similar manner, a high the PLR was strongly correlated with the presence of B-symptoms (OR, 2.22; 95% CI, 1.69-2.93, p<0.001), a high lactate dehydrogenase level (OR, 2.98; 95% CI, 2.19-4.06, p<0.001), a higher tumour stage (OR, 1.84; 95% CI, 1.08-3.13, p=0.03). Nevertheless, there was no significant correlation between a high the PLR and a high Eastern Cooperative Oncology Group performance status ≥2 (OR, 1.44; 95% CI, 0.69-3.02, p=0.33), a high bone marrow infiltration (OR, 1.02; 95% CI, 0.60-1.74, p=0.94), a person's gender (OR, 1.20; 95% CI, 0.93-1.55, p=0.17); age (OR, 0.89; 95% CI, 0.69-1.15, p=0.37); and cell of origin (OR, 1.00; 95% CI, 0.71-1.39, p=0.98). Conclusions: The impact of the PLR on DLBL may be substantial as a technique to enhance prognosis. Patients with DLBL who have a high the PLR may be at an independent risk for having a poor prognosis. To prevent potential problems, we advise keeping track of patients with a high platelet-to-lymphocyte ratio. | ||||
| Keywords | ||||
| platelet to lymphocyte ratio; Diffuse large B-cell lymphoma; overall survival; progression-free survival; B symptoms; elevated lactate dehydrogenase; higher tumor stage; Eastern Cooperative Oncology Group performance status; international prognostic index; Infiltration of bone marrow | ||||
|
Statistics Article View: 157 PDF Download: 137 |
||||
